EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphoma(biopharminternational.com)
biopharminternational.com
EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphoma
https://www.biopharminternational.com/view/european-commission-approves-tepkinly-plus-r2-as-first-bispecific-based-therapy-for-relapsed-or-refractory-follicular-lymphoma
1 comments
Because your title mentions EC, I just learned it’s the EC that approves the market authorisation. I always thought it was the EMA but apparently this is “just” a recommendation and in some cases the EC and EMA disagree.